Vibration-controlled transient elastography (VCTE), which measures liver stiffness, has become an important tool for evaluating patients with nonalcoholic fatty liver disease (NAFLD). We aimed to determine the diagnostic accuracy of VCTE in detection of NAFLD in a multicenter cohort of patients.
N onalcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver disease in the United States.
1 NAFLD exists as 2 predominant histologic subtypes: nonalcoholic fatty liver (NAFL) and nonalcoholic steatohepatitis (NASH). 2 NAFL is associated with a relatively benign clinical course, whereas NASH is associated with an increased risk of progressive fibrosis and cirrhosis. 3 In NAFLD, liver biopsy remains the gold standard for diagnosis, assessing activity, and staging fibrosis. However, the routine use of liver biopsy is limited by its invasive nature, risk of complications, cost, sampling error, and poor patient acceptance. 4, 5 This underscores an urgent need for noninvasive and accurate methods for disease detection and staging. Although there are currently no reliable noninvasive means of differentiating NAFL from NASH, noninvasive models that correlate with individual histologic parameters have been developed. 6, 7 Hepatic steatosis and fibrosis are 2 of the most studied histologic parameters because they are essential in disease diagnosis and staging, respectively. Although several noninvasive methods for assessing steatosis and fibrosis have been evaluated, these all have major limitations. 8 Vibration-controlled transient elastography (VCTE) measures the speed of a mechanically generated shear wave across the liver to derive a liver stiffness measurement (LSM), a marker of hepatic fibrosis. 9 Measuring the attenuation of ultrasound signal through the liver is used to derive the controlled attenuation parameter (CAP), which is measured simultaneously with LSM as a marker of hepatic steatosis. 10 The performance of VCTE using the standard M probe in NAFLD was limited by high failure rates in patients with a higher body mass index (BMI) and skin-toliver-capsule distance. 11 To circumvent the high failure rate in obese patients, an XL probe was developed. 12 To further reduce the failure rate and standardize methodology, Fibroscan 502 Touch (Paris, France), a probe selection software tool that automatically determines the choice of the probe based on skin-to-capsule distance, was developed. With these improvements, the failure rate of VCTE was reported to be less than 5%. 13 Despite the increasing literature regarding the use of VCTE in NAFLD, there are only a few single-center studies that have evaluated the accuracy of both medium (M) and XL probes in American cohorts. 14, 15 The aim of the current study was to examine the diagnostic accuracy of VCTE in assessing steatosis and fibrosis in a multicenter cohort of American adults with biopsy-proven NAFLD.
Methods

Study Design
All subjects included in this study were prospectively enrolled as part of the National Institutes of Health-funded NASH Clinical Research Network (NASH CRN) NAFLD Database 2 study, with inclusion and exclusion criteria as previously reported. 13 Eligible adult subjects (age, !18 y) were enrolled across 8 medical centers in the United States. 13 All subjects had biopsy-proven NAFLD within 12 months of the VCTE examination. Data were stored, monitored, and analyzed at the Data Coordinating Center at the John Hopkins Bloomberg School of Public Health. The Institutional Review Boards at participating centers approved the study (NCT01030484) and all participants provided written informed consent before enrollment. All authors reviewed and approved the manuscript before submission. This study was conducted according to Transparent Reporting of a multivariate prediction model for Individual Prognosis or Diagnosis for biomarker development (see Supplementary Material). 16 
Study Visit and Procedures
All subjects were evaluated at their respective medical center by a study investigator and research nurse after an overnight fast. Protocol-driven anthropometric measurements, study-specific questionnaires, and blood tests were collected. All eligible subjects underwent VCTE examinations between July 1, 2014, and July 31, 2017.
Liver Biopsy
All liver biopsy specimens were scored for features of NAFLD using the NASH CRN scoring system by the Pathology Committee of the NASH CRN, who were blinded to the VCTE and clinical data. 2 Hepatic steatosis was graded ordinally from 0 to 3 (grade 0, <5% steatosis; grade 1, 5%-33% steatosis; grade 2, 34%-66% steatosis; and grade 3, !67% steatosis). Hepatic fibrosis was quantified from stages 0 to 4 and for the purposes of this analysis advanced fibrosis was defined as fibrosis stage !3, with cirrhosis as stage 4. The presence of definite NASH was defined according to the NASH CRN criteria. Trained study coordinators or principal investigators performed all VCTE examinations using a standardized protocol. 13 Subjects were placed in the supine position with the right arm in maximal abduction and measurements were taken over the right hepatic lobe through an intercostal space. 13 All studies were started using the M probe with transition to the XL probe only if prompted by the device's automatic probe selection tool. Only cases with 10 or more valid acquisitions were used. Either the same or a different certified technician repeated the VCTE examination at the same session. The mean of the 2 VCTE examinations was used to obtain higher statistical power owing to lower variability when using means as opposed to a single measurement. To evaluate the impact of using the first reading compared with the means of the 2 VCTE examinations, summary statistics between the first and second examinations were compared. Unreliability of LSM was defined as interquartile range (IQR)/median greater than 30% and technical failure was defined by the inability to obtain 10 valid measurements. The LSM and CAP measurements used for this analysis were the means of the medians obtained with the 2 examinations. If 1 examination was missing or had unreliable data, the data from the completed examination was used. 13 
Statistical Analysis
Summary statistics include means, SDs, and percentages. Diagnostic statistics included sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and were cross-validated (using the jack-knife procedure) using the area under the receiver operating characteristic (AUROC) and 95% CIs. Diagnostic statistics and LSM cut-off values for increasing pairwise fibrosis stages (0 vs 1-4, 0-1 vs 2-4, 0-2 vs 3-4, and 0-3 vs 4) and CAP cutoff values for increasing pairwise steatosis grades (0 vs 1-3, 0-1 vs 2-3, and 0-2 vs 3) were estimated, as follows: (1) optimized sensitivity and specificity (via Youden Index), (2) sensitivity fixed at 90%, and (3) specificity fixed at 90%. Similarly, diagnostic statistics for detecting the presence of NASH using LSM, CAP, and the combination of CAP and LSM were determined. To evaluate the impact of the time interval between liver biopsy and VCTE, the cohort was subdivided into those who had a liver biopsy and VCTE within 30 days vs greater than 30 days. The diagnostic accuracy of VCTE in those 2 cohorts was evaluated by comparing the AUROC. Finally, sensitivity analysis was performed to assess the performance of VCTE between the first and second measurements.
To evaluate the impact of the liver histology on LSM, multiple linear regression models were constructed with steatosis, lobular and portal inflammation, ballooning, fibrosis, and BMI as candidate covariates and LSM as the outcome variable. To evaluate the impact of liver histology on CAP, multiple linear regression models were constructed with steatosis, portal and lobular inflammation, ballooning, fibrosis, and body mass index as candidate covariates, and CAP as the outcome variable. Final model selection was based on Akaike's Information Criteria. Analyses were conducted using SAS (version 9.3; SAS System for Windows, Cary, NC) and Stata (Stata Statistical Software: release 14; StataCorp LP, College Station, TX).
Results
Study Population
A total of 393 subjects met the inclusion criteria and were included in the analysis. Thirty-five subjects had missing CAP data while using the XL probe at the beginning of the study because software to compute CAP values was not available on the XL probe. The median absolute value of the time from liver biopsy to VCTE was 49 days (quartiles, 25, 78 d). The mean (AESD) age and BMI of the cohort was 51 AE 11 years and 34 AE 6 kg/m 2 , respectively ( Table 1 ). The distribution of biopsy fibrosis stage 0, stage 1, stage 2, stage 3, and stage 4 was 24%, 25%, 19%, 23%, and 9%, respectively. The distribution of biopsy steatosis grade for grade 0, 1, 2, and 3 was 5%, 38%, 30%, and 27%, respectively. Twenty-one (2.7%) of the 786 LSM measurements had unreliable results, and the failure rate was 3.7% (reasons for failure were as follows: 7 subjects had a skin-tocapsule distance >3.5 cm; 4 cases in which the machine was not working or available, and 4 cases in which the patient stopped or refused).
Performance Diagnostics of Liver Stiffness Measurements
The median LSM scores for fibrosis stages 0, 1, 2, 3, and 4 were 5. Table 2 ). The LSM cut-off values with sensitivity fixed at 90% for differentiating between dichotomous fibrosis stages were as follows: 4.9 kPa for stage 0 vs stages 1 to 4; 5.6 kPa for stages 0 to 1 vs stages 2 to 4; 6.5 kPa for stages 0 to 2 vs stages 3 to 4; and 12.1 kPa for stages 0 to 3 vs stage 4. By using these LSM cut-off values, the PPVs were 0.80, 0.62, 0.45, and 0.34, and the NPVs were 0.48, 0.80, 0.91, and 0.99 for discriminating between stage 0 vs stages 1 to 4, stages 0 to 1 vs stages 2 to 4, stages 0 to 2 vs stages 3 to 4, and stages 0 to 3 vs stage 4, respectively (Table 2 ). In contrast, with specificity fixed at 90%, the LSM cut-off values for discriminating fibrosis stage 0 vs stages 1 to 4, stages 0 to 1 vs stages 2 to 4, stages 0 to 2 vs stages 3 to 4, and stages 0 to 3 vs stage 4 were 9.4 kPa, 11.9 kPa, 12.1 kPa, and 14.9 kPa, respectively. The PPVs were 0.93, 0.80, 0.71, and 0.41, respectively, for differentiating between stage 0 vs stages 1 to 4, stages 0 to 1 vs stages 2 to 4, stages 0 to 2 vs stages 3 to 4, and stages 0 to 3 vs stage 4, while the corresponding NPVs were 0.34, 0.59, 0.80, and 0.97 (Table 2) . Finally, the cut-off value optimizing sensitivity and specificity for differentiating stage 0 from stages 1 to 4 was 8.6 kPa; stages 0 to 1 vs stages 2 to 4 was 8.6 kPa; stages 0 to 2 vs stages 3 to 4 was 8.6 kPa; and stages 0 to 3 vs stage 4 was 13.1 kPa ( Table 2 ). The diagnostic accuracy of LSM was not altered by the time interval between liver biopsy and VCTE (Table 3) . Finally, sensitivity analysis showed no difference between LSM measurements from the first and second examinations (Supplementary Tables 1 and 2 ).
Performance Diagnostics of Controlled Attenuation Parameter
The median CAP scores for steatosis grades 0, 1, 2, (Table 4) . At sensitivity fixed at 90%, a cut-off value of 263 dB/m provided 0.35 specificity, 0.96 PPV, and 0.15 NPV for detecting the presence of !5% steatosis. When the specificity was fixed at 90%, a cut-off value 353 dB/m provided sensitivity of 0.29, PPV of 0.98, and NPV of 0.06. The cut-off values for differentiating between steatosis grades 0 to 1 vs grades 2 to 3 and steatosis grades 0 to 2 vs grade 3 at 90% fixed sensitivity were 280 and 274 dB/m and at 90% fixed specificity were 367 and 380 dB/md specificity, respectively. The cut-off values optimizing sensitivity and specificity for differentiating steatosis grade 0 vs grades 1 to 3 was 285 dB/m; grades 0 to 1 vs grades 2 to 3 was 311 dB/ m; and grades 0 to 2 vs grade 3 was 306 dB/m (Table 3) . Finally, the diagnostic accuracy of CAP was similar whether the time interval between liver biopsy and VCTE was fewer than 30 days or more than 30 days (Table 3) . By using sensitivity analysis, there was no difference between CAP measurements obtained between the first and second examinations (Supplementary Tables 1 and 2 ).
Regression Models
In regression analysis, fibrosis (b-coefficient, 4.3 kPa/ stage; 95% CI, 3.4-5.2; P < .001) and BMI (b-coefficient, ; 95% CI, -0.03 to 0.27; P ¼ .10) were related directly to LSM, whereas an inverse relationship between steatosis grade (b-coefficient, -1.8 kPa/grade; 95% CI, -2.9 to -0.7; P ¼ .001) and ballooning (b-coefficient, -1.1 kPa/grade; 95% CI, -2.5 to 0.4; P ¼ .16) was found. Portal and lobular inflammation were not related to LSM. A direct and significant relationship between CAP and steatosis (b-coefficient, 17 dB/m/grade; 95% CI, 12-22; P < .001), portal inflammation (b-coefficient, -5.9 dB/m/grade; 95% CI, -13.0 to 1.2; P ¼ .10), and BMI (bcoefficient, 2.8 dB/m/kg/m 2 ; 95% CI, 2.1-3.5; P < .001) was found (Supplementary Table 3) .
Although BMI was related significantly to both LSM and CAP, the diagnostic performance of LSM for assessing fibrosis and CAP for assessing steatosis did not vary by BMI category (Supplementary Table 4) . The relationship between steatosis grade and LSM did not vary by the presence or absence of advanced fibrosis. Similarly, after adjusting for BMI, no significant relationship between LSM and CAP was noted (data not shown).
Diagnostic Accuracy of Vibration-Controlled Transient Elastography in Predicting Nonalcoholic Steatohepatitis
Among 358 subjects with definite NASH, the crossvalidated AUROC for LSM was 0.74 (95% CI, 0.68-0.79), with an odds ratio (OR) of 1.078 (95% CI, 1.034-1.123) per kPa (P < .001) for detecting the presence of NASH. 
Discussion
An important unmet need in NAFLD is a point-of-care test that can aid in the detection and identification of advanced fibrosis. VCTE can detect steatosis and fibrosis simultaneously, but there is a paucity of data defining the optimal use of VCTE in American cohorts.
14, 15 The current study evaluated the diagnostic accuracy of VCTE in a multicenter cohort with histologically confirmed NAFLD to assess parameters for clinical use by identifying thresholds that are highly sensitive or specific.
Early detection of NAFLD is vital to allow sufficient time to implement strategies aimed at favorably altering the natural history of the disease. The CAP value is associated positively with the severity of hepatic steatosis and the cross-validated AUROC is 76% for classifying patients with !5% steatosis on histology. This cut-off value (CAP, 263 dB/m) is similar to the previously proposed cut-off value in a US cohort.
14 In addition to clinical care, the CAP value also may be used as an adjunct tool in regulatory science to allow for subject enrichment in early phase clinical trials with nonhistologic end points. A CAP value less than 274 dB/m has an 84% NPV for grades 0 to 2 steatosis (ie, excludes grade 3 steatosis), suggesting that cut-off value may offer some clinical and research utility. In contrast, the accuracy of CAP in separating steatosis grade, particularly grades 2 and 3, was suboptimal, a finding that confirms prior reports. 10, 14 Figure 2. Controlled attenuation parameter according to steatosis grade. In NAFLD, hepatic fibrosis is a key predictor of liverrelated outcomes 3, 17 and VCTE can be used to detect fibrosis, especially in its advanced stage. Although VCTE is not a confirmatory test, it can help identify patients in whom additional histologic assessment may be warranted, while avoiding liver biopsies in patients with none to minimal fibrosis. Identifying optimal cut-off values of VCTE depends on the context of use for VCTE. Noninvasive biomarkers aim to either minimize false negatives (ie, high sensitivity) or to minimize false positives (ie, high specificity), depending on whether VCTE is being used as a screening modality or a tool to identify NAFLD patients with fibrosis with a great degree of certainty. Moderate fibrosis is linked to liver-related outcomes and mortality, 17 and a LSM less than 5.6 kPa has a NPV of 80% for excluding moderate fibrosis. Similarly, a less invasive approach can be used in patients with a LSM less than 6.5 kPa because the presence of advanced fibrosis can be excluded with at least 91% certainty. Higher LSM values allow for greater specificity and can be used to identify individuals in whom additional confirmatory histologic assessment may be warranted. Furthermore, we also applied the cut-off values proposed by the Baveno IV consensus for the detection of advanced fibrosis in our cohort and the published data. 15, 18 The cut-off value of greater than 9.9 kPa had a PPV of 46% and 64% for detecting advanced fibrosis in the cohorts studied by Tapper et al 15 and the NASH CRN, respectively (Supplementary Table 3 ). The higher PPV observed in the NASH CRN cohort likely was owing to the higher prevalence of advanced fibrosis within the NASH CRN cohort (32% vs 18%). Conversely, using a cut-off value greater than 15 kPa yielded a NPV of 75% within the NASH CRN cohort. These findings are in line with the assertion that VCTE has good accuracy at extremes, with low LSM essentially ruling out advanced disease and higher LSM values ruling in cirrhosis. 19 An interesting inverse relationship between LSM and steatosis grade and cytologic ballooning was noted, as has been reported previously. 20 This likely represents the disappearance of classic histologic components of NAFLD as patients progress to advanced fibrosis. 21 Although inflammation has been shown to impact LSM in patients with chronic liver disease, no such association was noted in the current study. 22, 23 This likely was because inflammation in NAFLD often is less severe than is found in viral hepatitis. Finally, the diagnostic accuracy of VCTE for distinguishing NAFL from NASH also was poor.
There were several notable strengths of the current study. This multicenter study evaluated the accuracy of VCTE using both M and XL probes and Fibroscan 502 Touch software in a US cohort using a standardized and uniform protocol. Because of the multicenter design, the results are more generalizable than previously reported single-center experiences. 14, 15 The sample size of the current study also was larger than prior US studies, with more equal distribution of histologic parameters, particularly steatosis and fibrosis. Finally, we found that a single patient scan for both LSM (SD, 10.9 kPa) and CAP (SD, -50 dB/m) are nearly as precise as the average of the 2 scans LSM (SD, 11.0 kPa) and CAP (SD, 48 dB/m), with no bias between the first and second scans, thus a single scan can be used unless there is some reason other than increased precision to do so.
A potential limitation of the study was that VCTE and liver biopsy were not performed simultaneously. However, because fibrosis evolves slowly, it is unlikely that the relatively short delay between biopsy and VCTE had any significant impact on LSM. Although the delay between liver biopsy and VCTE did not impact the diagnostic accuracy of LSM or CAP, the power to detect such interactions was low. The current study evaluated patients enrolled in an observational research study, and the diagnostic performance of VCTE cannot be extrapolated to primary care clinics where the prevalence and the severity of disease may be different. Thus, the PPV and NPV reported in the NASH CRN cohort may be different than in primary care clinics.
In summary, VCTE is a noninvasive point-of-care tool that can be used in clinical practice for identifying steatosis and advanced fibrosis in patients with NAFLD. VCTE may be useful in identifying patients in whom additional histologic assessment may be warranted owing to the presence of advanced fibrosis, while excluding patients without significant fibrosis in whom a liver biopsy may be unnecessary. 
